Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an update.
On March 25, 2025, XORTX Therapeutics Inc. released its consolidated financial statements for the years ending December 31, 2024, 2023, and 2022. The report, audited by Davidson & Company LLP, highlights recurring operational losses, raising concerns about the company’s ability to continue as a going concern. Despite these challenges, the financial statements were deemed to fairly represent the company’s financial position in accordance with IFRS standards. The company has undergone a change in accounting policy and made revisions to previous financial statements, which were audited and found appropriate. This announcement underscores the financial hurdles XORTX faces, impacting its operational stability and posing significant considerations for stakeholders.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing therapies for the treatment of progressive kidney disease and other health conditions related to excess uric acid. The company is primarily engaged in research and development activities aimed at creating innovative solutions to address unmet medical needs in this niche market.
YTD Price Performance: -16.87%
Average Trading Volume: 7,923
Technical Sentiment Signal: Buy
Current Market Cap: C$5.22M
For an in-depth examination of XRTX stock, go to TipRanks’ Stock Analysis page.